veoexrmpzt
Dołączył: 21 Lut 2011
Posty: 371
Przeczytał: 0 tematów
Ostrzeżeń: 0/5
Skąd: England
|
 Wysłany: Czw 20:34, 17 Mar 2011 Temat postu: adidas scarpe ckq pnl civf hme |
 |
|
Overseas listing of newly approved drugs new formulation of new agents (94)
ax innovative Preparation of microspheres release the drug to the small intestine rather than the stomach, can reduce adverse drug reactions. In addition, the permeability of drugs on a large organization. Azithromycin half by a long period in the entire treatment process can make only a single dose of medication. Such short-term high-dose administration to patients with single-dose antibiotic treatment, improve compliance and to minimize the extent of antibiotic resistance. This product is mild to moderate adverse reactions. In the pivotal clinical study. After taking a single dose Zmax2g adults the most common adverse reactions were diarrhea / stool thin (11.6%), nausea (3.9%), abdominal pain (2.7%), headache (1.3%) and vomiting (1 .1%), taking the majority of Zmax were diarrhea can be stopped in 2 days to the U.S. FDA approval JE · 25.5 Ze it too by listing the U.S. FDA approved injection Ami Lin (Amylin) Inc. and Eli Lilly that by Ze Pacific (exenatide) injection (brand name: Byetta) listed,[link widoczny dla zalogowanych], adjuvant therapy with metformin and sulfonylurea drugs can not control blood glucose in patients with type Ⅱ. This product is called the first incretin mimetic (incretinmimetics) of a new class of diabetes drugs treatment of type Ⅱ. Presents a lot of people incretin hormone like glucagon-like peptide a 1 (GLP-1) a similar effect: consumption caused by the secretion of GLP-1, which regulate blood sugar on the stomach, liver, pancreas, and brain and other organs have multiple roles. Incretin mimetic role of insulin analog called incretin hormone that the body's own anti-diabetic or have lower blood sugar. These effects include the human body can produce postprandial blood glucose concentration on the production of insulin response and inhibit glucagon. Reduce the absorption of nutrients and food rates. This product by reducing the postprandial and fasting glucose in order to better long-term control of blood glucose through multiple mechanisms play a role: includes only the higher concentration in the blood when stimulated insulin secretion. Restore the loss of insulin-producing pancreatic cells in patients with type Ⅱ diabetes insulin I of the reaction. In clinical studies,[link widoczny dla zalogowanych], this product can also reduce body weight in most patients. In addition to the product as an oral adjuvant therapy drugs, the U.S. FDA approval of its conventional single drug is the treatment of type Ⅱ diabetes. Byetta patients into their drug fixed-dose pre-filled pen-shaped device (each dose of 5 or 101 ~ g), subcutaneous injection before breakfast and dinner. 30 weeks 3 controlled clinical studies have shown. Byetta side effects are usually mild to moderate. Primarily dose-related nausea. 6 Tosi monoclonal antibody injection approved for production in Japan, Chugai's Tosi monoclonal antibody (tocilizumab) injection (brand name: Actemra200) approved for production in Japan. The strains of a humanized anti-human IL-6 (IL-6), a pharmaceutical information by 26 * 21 2005 Vol body monoclonal antibody,[link widoczny dla zalogowanych], is Japan's first listed on antibody drugs. Intravenous infusion for the treatment of Castleman disease (giant lymph node hyperplasia). In Japan, Phase Ⅱ clinical study,[link widoczny dla zalogowanych], the following week to give Tosi antibody 8mg/kg, a total of 8 times. The results showed that a single anti-inflammatory treatment in order to Tosi during the inflammatory markers (CRP, fibrinogen, ESR), general fatigue, anemia, and albumin have been significantly improved to reduce hyperlipidemia. Long-term (up to 1568 days, on average 1191 days) repeated treatment, but also to maintain a significant effect. Including the improvement of inflammatory markers. Chinese and foreign pharmaceutical companies are in Japan the treatment of rheumatoid arthritis of the product (RA) phase Ⅲ clinical research, to approve the plan submitted in 2006, please: in cooperation with Roche, the other a total of more than 20 countries, over 4000 cases of RA patients Phase Ⅲ clinical research, plan approval application submitted in 2007. 7 U.S. FDA approval of Microcyn protection devices listed U.S. FDA approval record Oukulusi Innovation Sciences (OculusInnovativeSciences) using technology to produce the Dermacyn Microcyn care record device market. For acute and traumatic wounds and burns wetting, lubrication and debridement. Preparation of using Microcyn neutral pH, the peroxide solution, without dilution or mixing, nor do they need special processing and disposal. It uses sophisticated multi-chamber electrolysis process,[link widoczny dla zalogowanych], choice of production and separation of ion species. This process can produce a neutral pH, and the final product solution of chloride concentration is minimized. This product has been approved in Europe as a creating programs for the treatment of acute care and chronic wounds (eg diabetic foot ulcers and burns, etc.); in Mexico allowed to be used as disinfectants, antibacterial agents and fungicides, and products have been widely sold for the treatment of numerous wounds and burns. Huang Sheng Yan Abstract
Post został pochwalony 0 razy
|
|
